Spearmint extract Neumentix downregulates amyloid-β accumulation by promoting phagocytosis in APP23 mice

IF 2.7 4区医学 Q3 NEUROSCIENCES

Brain Research Pub Date : 2025-06-02 DOI:10.1016/j.brainres.2025.149752

Xinran Hu , Ryuta Morihara , Yusuke Fukui , Yuting Bian , Hongming Sun , Ricardo Satoshi Ota-Elliott , Hiroyuki Ishiura , Koji Abe , Toru Yamashita

{"title":"Spearmint extract Neumentix downregulates amyloid-β accumulation by promoting phagocytosis in APP23 mice","authors":"Xinran Hu , Ryuta Morihara , Yusuke Fukui , Yuting Bian , Hongming Sun , Ricardo Satoshi Ota-Elliott , Hiroyuki Ishiura , Koji Abe , Toru Yamashita","doi":"10.1016/j.brainres.2025.149752","DOIUrl":null,"url":null,"abstract":"<div><div>In recent years, many researchers have focused on natural compounds that can effectively delay symptoms of Alzheimer’s disease (AD). The spearmint extract Neumentix, which is rich in phenolic compounds, has been shown to reduce inflammatory responses and oxidative stress in mice. However, the effect of Neumentix on AD has not been thoroughly studied. In this study, APP23 transgenic female and male mice were administered Neumentix orally from 4 to 18 months of age at a dosage of 2.65 g/kg/day (containing 0.41 g/kg/day of rosmarinic acid). The impact was evaluated by behavioral tests and histological analyses and compared with APP23 mice to which Neumentix was not administered. The results showed that Neumentix administration increased the survival rate of APP23 mice and effectively reduced Aβ accumulation by enhancing its phagocytosis by microglial cells. These findings suggest that Neumentix is a potential natural nutritional treatment for improving the progression of AD.</div></div>","PeriodicalId":9083,"journal":{"name":"Brain Research","volume":"1863 ","pages":"Article 149752"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0006899325003129","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, many researchers have focused on natural compounds that can effectively delay symptoms of Alzheimer’s disease (AD). The spearmint extract Neumentix, which is rich in phenolic compounds, has been shown to reduce inflammatory responses and oxidative stress in mice. However, the effect of Neumentix on AD has not been thoroughly studied. In this study, APP23 transgenic female and male mice were administered Neumentix orally from 4 to 18 months of age at a dosage of 2.65 g/kg/day (containing 0.41 g/kg/day of rosmarinic acid). The impact was evaluated by behavioral tests and histological analyses and compared with APP23 mice to which Neumentix was not administered. The results showed that Neumentix administration increased the survival rate of APP23 mice and effectively reduced Aβ accumulation by enhancing its phagocytosis by microglial cells. These findings suggest that Neumentix is a potential natural nutritional treatment for improving the progression of AD.

查看原文本刊更多论文

留兰薄荷提取物新清通过促进吞噬作用下调APP23小鼠淀粉样蛋白-β的积累。

近年来，许多研究人员都在关注能够有效延缓阿尔茨海默病（AD）症状的天然化合物。薄荷提取物neuentix富含酚类化合物，已被证明可以减少小鼠的炎症反应和氧化应激。然而，新美特对阿尔茨海默病的影响尚未得到充分的研究。在本研究中，APP23转基因雌性和雄性小鼠在4 ~ 18 月龄时口服新替婷，剂量为2.65 g/kg/天（含0.41 g/kg/天迷迭香酸）。通过行为学测试和组织学分析评估影响，并与未给药的APP23小鼠进行比较。结果表明，新替纽通过增强小胶质细胞对Aβ的吞噬作用，提高了APP23小鼠的存活率，有效降低了Aβ的积累。这些发现表明，新孟婷是一种潜在的天然营养治疗，可以改善阿尔茨海默病的进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Brain Research 医学-神经科学

CiteScore

5.90

自引率

3.40%

发文量

268

审稿时长

47 days

期刊介绍： An international multidisciplinary journal devoted to fundamental research in the brain sciences. Brain Research publishes papers reporting interdisciplinary investigations of nervous system structure and function that are of general interest to the international community of neuroscientists. As is evident from the journals name, its scope is broad, ranging from cellular and molecular studies through systems neuroscience, cognition and disease. Invited reviews are also published; suggestions for and inquiries about potential reviews are welcomed. With the appearance of the final issue of the 2011 subscription, Vol. 67/1-2 (24 June 2011), Brain Research Reviews has ceased publication as a distinct journal separate from Brain Research. Review articles accepted for Brain Research are now published in that journal.